ARCHIVES

FDA Approives Lilly’s Alimta For 1st-Line Metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 31 No. 9 | September 26, 2008

Download PDF Visit The Full Archive

Related Articles

Study: Nine Years After Diagnosis 9.3% of Survivors Still Smoke

August 29, 2014

Rall, FDA Chief On AACR Panel

April 27, 1979

Calif., Illinois Enact ACCC Model Law On Reimbursement

October 23, 1992

Two Breast Cancer Program Announcements Listed On Screening, Genetic Susceptibility

February 1, 1980

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

NCI Offers Coded Serum Panels

May 28, 1982